AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17764549 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 24
Study 17764549 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary intervention
Number of subjects: 24
Study 14693537 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine once daily
Number of subjects: 60
Study 11898726 — intervention group
Group type: EXPERIMENTAL
Intervention: isoptine
Number of subjects: 0
Study 11898726 — intervention group
Group type: EXPERIMENTAL
Intervention: rhythmonorm
Number of subjects: 0
Study 11898726 — intervention group
Group type: EXPERIMENTAL
Intervention: allapinin
Number of subjects: 0
Study 11898726 — intervention group
Group type: COMPARATOR
Intervention: allapinin, rhythmonorm, isoptine
Number of subjects: 0
Study 9825192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 56
Study 9825192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8138400 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study 8138400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1670617 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 27
Study 1670617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7071166 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandages worn for eight hours
Number of subjects: 146
Study 7071166 — intervention group
Group type: COMPARATOR
Intervention: Compression bandages worn for three weeks
Number of subjects: 146
Study 7071166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure under the bandage applied at the end of the operation
Number of subjects: 146
Study 29241345 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus (n = 22)
Number of subjects: 65
Study 29241345 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (n = 22)
Number of subjects: 65
Study 29241345 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 21)
Number of subjects: 65
Study 29948457 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐switched KTP 532‐nm nanosecond laser
Number of subjects: 30
Study 29948457 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP 532‐nm picosecond laser
Number of subjects: 30
Study 29948457 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 27041454 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 66
Study 27041454 — intervention group
Group type: COMPARATOR
Intervention: No Delirium
Number of subjects: 66
Study 25609853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30
Study 25609853 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Number of subjects: 30
Study 25609853 — intervention group
Group type: COMPARATOR
Intervention: Placebo SM (control group)
Number of subjects: 30
Study 21070222 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC (NT-proBNP guided care)
Number of subjects: 190
Study 21070222 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 190
Study 21070222 — intervention group
Group type: EXPERIMENTAL
Intervention: HNC (Home-based Nurse Care)
Number of subjects: 190
Study 19206035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated inpatient rehabilitation (three weeks and another week at a future date)
Number of subjects: 0
Study 19206035 — intervention group
Group type: COMPARATOR
Intervention: Four-week inpatient treatment
Number of subjects: 0
Study 17924971 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood samples
Number of subjects: 61
Study 17924971 — intervention group
Group type: COMPARATOR
Intervention: Venous blood samples
Number of subjects: 61
Study 17924971 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous blood stimulated with PHA
Number of subjects: 61
Study 17924971 — intervention group
Group type: COMPARATOR
Intervention: Capillary blood stimulated with PHA
Number of subjects: 61
Study 17924971 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood
Number of subjects: 61
Study 17924971 — intervention group
Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 61
Study 17924971 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood stimulated with PAM3Cys and PPD
Number of subjects: 61
Study 17924971 — intervention group
Group type: COMPARATOR
Intervention: Venous blood stimulated with PAM3Cys and PPD
Number of subjects: 61
Study 15207897 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 932
Study 12207834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (50 : 50) CLA
Number of subjects: 51
Study 12207834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g cis‐9,trans‐11-trans‐10,cis‐12 isomeric blend (80 : 20) CLA
Number of subjects: 51
Study 12207834 — intervention group
Group type: COMPARATOR
Intervention: linoleic acid (control)
Number of subjects: 51
Study 9510003 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 9510003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8077528 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge to 6-month incidence of nonfatal reinfarction
Number of subjects: 8907
Study 8077528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac ineligibility for exercise test
Number of subjects: 8907
Study 8077528 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 8907
Study 8077528 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina at follow-up
Number of subjects: 8907
Study 8077528 — intervention group
Group type: EXPERIMENTAL
Intervention: History of angina (in 6,580 patients with echocardiographic and electrocardiographic monitoring)
Number of subjects: 8907
Study 2466454 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 144
Study 31932108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 on days 1, 8, and 15 (phase 1b)
Number of subjects: 33
Study 31932108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg once daily and fosbretabulin 54 mg/m2 (experimental arm)
Number of subjects: 33
Study 31932108 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib 800 mg once daily (control arm)
Number of subjects: 33
Study 31300995 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of gastroparesis patients
Number of subjects: 47
Study 31300995 — intervention group
Group type: COMPARATOR
Intervention: Caregivers of GERD patients
Number of subjects: 47
Study 31300995 — intervention group
Group type: COMPARATOR
Intervention: Caregivers of healthy volunteers (HVs)
Number of subjects: 47
Study 31300995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall caregiver burden
Number of subjects: 47
Study 31300995 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of gastroparesis and other comorbidities
Number of subjects: 47
Study 28285280 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 s)
Number of subjects: 78
Study 28285280 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60 s) with ergometrine (500 µg)
Number of subjects: 78
Study 28285280 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (10 s)
Number of subjects: 78
Study 26081658 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment
Number of subjects: 75
Study 26081658 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 26081658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin levels
Number of subjects: 75
Study 26081658 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic scores (mSASSS)
Number of subjects: 75
Study 24307311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaiqin Chengqi Decoction (CQCQD) administered by gastric perfusion (50 mL/2 h) and retention enema (200 mL/6 h) for 7 days
Number of subjects: 35
Study 24307311 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35
Study 21876349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bindarit (1,200 mg/day)
Number of subjects: 22
Study 21876349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19236643 — intervention group
Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) propofol
Number of subjects: 60
Study 19236643 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg x kg(‐1) propofol
Number of subjects: 60
Study 19236643 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg x kg(‐1) propofol
Number of subjects: 60
Study 15992791 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial language input with multiple generalizations
Number of subjects: 2
Study 12631162 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal derangement of the TMJ
Number of subjects: 30
Study 12631162 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised muscle tenderness of the temporomandibular system
Number of subjects: 30
Study 11129620 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-fentanyl (group M) - intravenous midazolam 0.1 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Number of subjects: 16
Study 11129620 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (group P) - intravenous propofol 4 mg.kg‐1.h‐1 and fentanyl 25 micrograms.kg‐1 until sternotomy
Number of subjects: 16
Study 11129620 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 9085210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (10 micrograms administered intravenously)
Number of subjects: 0
Study 9085210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 8239010 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg clonidine
Number of subjects: 105
Study 8239010 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms/kg clonidine
Number of subjects: 105
Study 8239010 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg diazepam
Number of subjects: 105
Study 8239010 — intervention group
Group type: COMPARATOR
Intervention: 0.03 mg/kg oral atropine
Number of subjects: 105
Study 3010028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-blocker, 50 mg once per day)
Number of subjects: 17
Study 3010028 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 (beta 2-blocker, 20 mg t.i.d.)
Number of subjects: 17
Study 3010028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3010028 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551 (beta 2-blocker)
Number of subjects: 17
Study 3010028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-blocker)
Number of subjects: 17
Study 30766555 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes, 3 days per week for 12 weeks on treadmills
Number of subjects: 115
Study 30766555 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 115
Study 28077539 — intervention group
Group type: COMPARATOR
Intervention: Group R (remifentanil 0.30 µg kg‐1 min‐1)
Number of subjects: 120
Study 28077539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 20 µg kg‐1)
Number of subjects: 120
Study 28077539 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BF (remifentanil 0.30 µg kg‐1 min‐1 and pre‐anaesthesia butorphanol 10 µg kg‐1 combined with flurbiprofen axetil 0.5 mg kg‐1)
Number of subjects: 120
Study 28077539 — intervention group
Group type: COMPARATOR
Intervention: Group S (sufentanil 0.30 µg kg‐1)
Number of subjects: 120
Study 25591645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 62
Study 25591645 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no cerebrolysin)
Number of subjects: 62
Study 22729798 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (50% maximal voluntary contraction) during 1 min coronary balloon occlusion
Number of subjects: 65
Study 22729798 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (sedentary during coronary occlusion)
Number of subjects: 65
Study 20716014 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Nurse Support (N = 41)
Number of subjects: 121
Study 20716014 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) (N = 39)
Number of subjects: 121
Study 20716014 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control) (N = 41)
Number of subjects: 121
Study 17627739 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 684
Study 17627739 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 684
Study 17627739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 15672306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model analysis
Number of subjects: 30285
Study 15672306 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects meta-analysis
Number of subjects: 30285
Study 15672306 — intervention group
Group type: COMPARATOR
Intervention: Fixed effects model
Number of subjects: 30285
Study 15672306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model
Number of subjects: 30285
Study 15672306 — intervention group
Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 30285
Study 11823755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine with 500 mg probenecid
Number of subjects: 12
Study 11823755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg risperidone with 500 mg probenecid
Number of subjects: 12
Study 11823755 — intervention group
Group type: COMPARATOR
Intervention: 5 mg olanzapine alone
Number of subjects: 12
Study 11823755 — intervention group
Group type: COMPARATOR
Intervention: 1 mg risperidone alone
Number of subjects: 12
Study 10027031 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion, 30 mg.kg‐1.h‐1 (Group P; n = 12)
Number of subjects: 48
Study 10027031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.5 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.5; n = 12)
Number of subjects: 48
Study 10027031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.75 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.75; n = 12)
Number of subjects: 48
Study 10027031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine bolus, 0.25 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.25; n = 12)
Number of subjects: 48
Study 7717488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg-1
Number of subjects: 24
Study 7717488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/midazolam 2 mg.kg-1 after midazolam pretreatment
Number of subjects: 24
Study 7717488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/esmolol 2 mg.kg-1 with esmolol
Number of subjects: 24
Study 7717488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 24
Study 2030491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized P4 supplementation (200 mg four times daily)
Number of subjects: 34
Study 2030491 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 34
Study 7211972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation
Number of subjects: 14
Study 7211972 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 14
Study 31612263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial (TT) technique
Number of subjects: 86
Study 31612263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 86
Study 31612263 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in (OI) technique
Number of subjects: 86
Study 31922707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered in the first year postpartum
Number of subjects: 170
Study 31922707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 170
Study 27514319 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal (femoral access)
Number of subjects: 240
Study 27514319 — intervention group
Group type: COMPARATOR
Intervention: Radial approach
Number of subjects: 240
Study 27514319 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal
Number of subjects: 240
Study 25034200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined standard PCNL and mini‐PCNL (group 1)
Number of subjects: 45
Study 25034200 — intervention group
Group type: COMPARATOR
Intervention: Combined standard PCNL and RIRS (group 2)
Number of subjects: 45
Study 24379596 — intervention group
Group type: EXPERIMENTAL
Intervention: Perirenal space blocking (PSB) + specialized medical therapy (SMT)
Number of subjects: 40
Study 24379596 — intervention group
Group type: COMPARATOR
Intervention: No perirenal space blocking (NPSB) + specialized medical therapy (SMT)
Number of subjects: 40
Study 21210281 — intervention group
Group type: COMPARATOR
Intervention: Task-related oxygen uptake during ADLs in CHF patients
Number of subjects: 23
Study 21210281 — intervention group
Group type: COMPARATOR
Intervention: Getting dressed in CHF patients
Number of subjects: 23
Study 21210281 — intervention group
Group type: COMPARATOR
Intervention: Sweeping the floor in CHF patients
Number of subjects: 23
Study 21210281 — intervention group
Group type: COMPARATOR
Intervention: Peak ventilation and peak heart rate during ADLs in CHF patients
Number of subjects: 23
Study 19725854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 24
Study 19725854 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 24
Study 17410506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS)
Number of subjects: 40
Study 17410506 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine
Number of subjects: 40
Study 15199619 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Wuzi Yanzong Granule (MWYG)
Number of subjects: 44
Study 15199619 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo leaf extraction
Number of subjects: 44
Study 11893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of epoetin (recombinant human erythropoietin)
Number of subjects: 0
Study 11893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal reduction (10%) in epoetin dose
Number of subjects: 0
Study 9810889 — intervention group
Group type: EXPERIMENTAL
Intervention: Elase ointment (proteolytic ointment)
Number of subjects: 84
Study 9810889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysin
Number of subjects: 84
Study 9810889 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAse
Number of subjects: 84
Study 9810889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ointment vehicle)
Number of subjects: 84
Study 9810889 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ointment (Elase)
Number of subjects: 84
Study 7701449 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms fenoterol
Number of subjects: 9
Study 7701449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2494014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing medium‐chain triacylglycerols (MCT) and long‐chain triacylglycerols (LCT)
Number of subjects: 16
Study 2494014 — intervention group
Group type: COMPARATOR
Intervention: Conventional emulsion containing only long‐chain triacylglycerols (LCT)
Number of subjects: 16
Study 836112 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 IU of human chorionic gonadotropin (HCG) intramuscularly daily for 30 days
Number of subjects: 11
Study 836112 — intervention group
Group type: COMPARATOR
Intervention: Diluent only (placebo)
Number of subjects: 11
Study 836112 — intervention group
Group type: COMPARATOR
Intervention: HCG and placebo groups
Number of subjects: 11
Study 31990912 — intervention group
Group type: EXPERIMENTAL
Intervention: CaFaSpA referral model (intervention)
Number of subjects: 679
Study 31990912 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (control)
Number of subjects: 679
Study 27693681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative foot mat use
Number of subjects: 127
Study 27693681 — intervention group
Group type: COMPARATOR
Intervention: Control (no foot mat use)
Number of subjects: 127
Study 25937461 — intervention group
Group type: EXPERIMENTAL
Intervention: MOtiVation and Enhancement (MOVE)
Number of subjects: 51
Study 25937461 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 51
Study 23428878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric meal with high fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8
Study 23428878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric meal with intermediate fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8
Study 23428878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric meal with low fiber and antioxidants (vitamin E, selenium, β‐carotene)
Number of subjects: 8
Study 23428878 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements before meal)
Number of subjects: 8
Study 20840349 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg twice weekly (BIW)
Number of subjects: 752
Study 20840349 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50mg weekly (QW)
Number of subjects: 752
Study 19053956 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost with 2% carteolol
Number of subjects: 15
Study 19053956 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost with 0.5% timolol
Number of subjects: 15
Study 19053956 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 15
Study 17320026 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of surrogate markers (bone mineral density, bone turnover markers, vertebral fracture assessment)
Number of subjects: 0